Daily Anesthesiology Research Analysis
Three impactful anesthesiology papers stand out today: a systematic review/meta-analysis supports dexmedetomidine as an opioid-sparing adjunct that also reduces emergence delirium in pediatric tonsillectomy; an interpretable machine-learning model accurately predicts clinically important GI bleeding in ICU patients; and a dose-finding study shows women with preeclampsia require 1.5× higher carbetocin to prevent uterine atony during Cesarean delivery.
Summary
Three impactful anesthesiology papers stand out today: a systematic review/meta-analysis supports dexmedetomidine as an opioid-sparing adjunct that also reduces emergence delirium in pediatric tonsillectomy; an interpretable machine-learning model accurately predicts clinically important GI bleeding in ICU patients; and a dose-finding study shows women with preeclampsia require 1.5× higher carbetocin to prevent uterine atony during Cesarean delivery.
Research Themes
- Opioid-sparing pediatric anesthesia and emergence delirium mitigation
- Interpretable machine learning for ICU risk prediction
- Optimizing uterotonic dosing in preeclampsia for hemorrhage prevention
Selected Articles
1. Dexmedetomidine in pediatric tonsillectomy: a systematic review with meta-analysis.
Across 16 RCTs, dexmedetomidine reduced perioperative opioid requirements and dose-dependently decreased emergence delirium in pediatric tonsillectomy. Evidence on PRAE and PONV was heterogeneous, partly due to inconsistent definitions across trials.
Impact: This synthesis supports an opioid-sparing, sedation-analgesia strategy with dexmedetomidine and quantifies benefits on emergence delirium, informing pediatric perioperative protocols.
Clinical Implications: Consider dexmedetomidine as an adjunct during pediatric tonsillectomy to reduce opioid exposure and emergence delirium, while standardizing PRAE definitions and monitoring to clarify respiratory safety.
Key Findings
- Dexmedetomidine was associated with lower perioperative opioid requirements compared with control.
- Emergence delirium incidence decreased in a dose-dependent manner with dexmedetomidine.
- Evidence for PRAE and PONV effects was heterogeneous due to variable definitions and effect sizes across trials.
Methodological Strengths
- PROSPERO-registered systematic review using Cochrane RoB 2 and GRADE with random-effects meta-analysis
- Dose–response exploration via random-effects meta-regression
Limitations
- Inconsistent PRAE definitions and variable dosing regimens across trials
- Limited number of trials per outcome (e.g., ED and PRAE), reducing precision
Future Directions: Large, standardized RCTs should define PRAE uniformly, refine dosing strategies, and assess safety and recovery endpoints including PONV and long-term behavior.
PURPOSE: We aimed to evaluate the effects of intravenous dexmedetomidine (DEX) on perioperative opioid requirements, and secondarily on perioperative respiratory adverse events (PRAE), emergence delirium (ED), and postoperative nausea and vomiting in pediatric patients undergoing tonsillectomy. METHODS: We conducted a systematic review with meta-analysis, searching seven databases up to 7 May 2024. We included randomized controlled trials of patients aged 18 yr or younger undergoing tonsillectomy, comparing intravenous DEX and opioids with opioids. Our primary outcome was perioperative opioid requirements, expressed as oral morphine equivalents (OME). The secondary outcomes included the incidences of perioperative respiratory adverse events (PRAE), emergence delirium (ED), and postoperative nausea and vomiting (PONV), We used the Cochrane Risk of Bias 2 tool and assessed the certainty of the evidence with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE). We used a pairwise random effects model to compute the risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs) of the effects of DEX on each outcome. To explore dose-dependent effects of DEX, we used a random effects meta-regression model. RESULTS: We included 16 trials in our systematic review, of which we analyzed 7 for opioid requirements, 4 for PRAE, 3 for ED, and 12 for PONV. Dexmedetomidine was associated with lower perioperative opioid requirements (MD, -0.25 mg·kg
2. An interpretable machine learning approach for predicting clinically important gastrointestinal bleeding in critically ill patients.
Using first-24-hour ICU data from 7,357 adults, an XGBoost model predicted clinically important GI bleeding with AUROC 0.84 and identified physiologic and laboratory predictors via SHAP. Traditional markers like early mechanical ventilation and stress-ulcer prophylaxis were not among the top contributors.
Impact: First interpretable ML model for CIGIB in ICU with strong discrimination and transparent predictor contributions, enabling targeted surveillance and prophylaxis research.
Clinical Implications: May support early, individualized risk stratification to allocate monitoring and prophylaxis; external validation and impact analyses are required before routine deployment.
Key Findings
- Among 7,357 ICU patients, 2.3% developed clinically important GI bleeding.
- XGBoost achieved AUROC 0.84 for predicting CIGIB using data from the first 24 hours.
- Top SHAP predictors were APACHE III, hematocrit, APTT, creatinine, and respiratory rate; early invasive ventilation and stress-ulcer prophylaxis were not top predictors.
Methodological Strengths
- Large cohort with clear exclusion to reduce label leakage and interpretable SHAP analyses
- Comparative modeling (XGBoost, Random Forest, L1-logistic) with multiple performance metrics
Limitations
- Single-center retrospective design without external validation
- Potential class imbalance and unmeasured confounding; clinical impact not yet tested
Future Directions: Prospective multicenter validation, calibration drift monitoring, and randomized impact studies testing ML-guided prophylaxis/monitoring strategies.
BACKGROUND: Clinically important gastrointestinal bleeding (CIGIB) is a serious complication in critically ill patients, contributing to prolonged ICU stays and increased mortality. Despite efforts to identify high-risk patients, no previous studies have employed machine learning models to predict CIGIB during ICU stay or identify key predictors in this context. METHODS: This single-center retrospective study included ICU patients aged 18 years or older admitted between 2017 and 2024. Patients with ICU stays of less than 24 h or GIB within 24 h of admission were excluded. Machine learning models, including XGBoost, Random Forest, and L1-regularized logistic regression, were trained using patient data from the first 24 h of ICU admission. Model performance was assessed using AUROC, precision, recall, and F1 scores. Shapley Additive Explanations (SHAP) were employed to evaluate key predictors. RESULTS: A total of 7357 ICU patients were included, of whom 171 (2.3%) experienced CIGIB. The XGBoost model demonstrated the highest predictive performance with an AUROC of 0.84. Key predictors included APACHE III scores, hematocrit levels, APTT, creatinine and respiratory rate, while invasive mechanical ventilation and stress ulcer prophylaxis within the first 24 h of ICU admission did not rank among the top 20 predictors based on SHAP values. CONCLUSIONS: This study represents the first application of machine learning for predicting CIGIB in ICU patients, providing valuable insights into risk stratification. The model demonstrated high predictive accuracy and interpretability, highlighting its potential to guide early intervention and prophylaxis. Further multi-center studies and interventional trials are needed to validate these findings and refine clinical risk prediction strategies.
3. Minimum effective dose of carbetocin for preventing uterine atony during Cesarean delivery in patients with and without preeclampsia: a biased sequential allocation study.
Using a triple-blind biased-coin sequential allocation, the study determined carbetocin dose requirements across 10–120 μg during Cesarean delivery under spinal anesthesia. Women with preeclampsia required approximately 1.5× higher doses to prevent intraoperative uterine atony compared with those without preeclampsia.
Impact: Directly addresses a dosing gap for a first-line uterotonic in a high-risk obstetric subgroup, with a rigorous dose-finding design.
Clinical Implications: For Cesarean delivery in preeclampsia under spinal anesthesia, anticipate higher carbetocin requirements to achieve adequate uterine tone; institutions may consider protocol adjustments while confirming safety.
Key Findings
- Triple-blind biased-coin sequential allocation evaluated carbetocin doses from 10 to 120 μg.
- Preeclampsia patients required approximately 1.5 times higher carbetocin dose to prevent uterine atony.
- Successful dose defined by satisfactory uterine tone at 2 minutes post-bolus without additional intraoperative uterotonics.
Methodological Strengths
- Triple-blind design minimizing measurement and performance biases
- Efficient biased-coin sequential allocation for ED90 estimation across a wide dose range
Limitations
- Nonrandomized single-center design with sample size not reported in abstract
- Exact ED90 values not provided in the abstract; external validity and safety profiles require confirmation
Future Directions: Confirm ED90 values in multicenter RCTs, evaluate hemodynamic safety and postpartum outcomes, and assess effectiveness in varied anesthesia techniques and populations.
PURPOSE: The aggregate data for successful use of carbetocin in patients at high risk of postpartum hemorrhage is fairly large. Nevertheless, there are scant data evaluating carbetocin in patients with preeclampsia and no established optimal dose. Therefore, we aimed to determine the minimum effective dose (the dose effective in 90% of the studied population [ED METHODS: We based this nonrandomized triple-blinded dose finding study on biased coin sequential allocation design. We enrolled all consenting nonlabouring parturients aged > 18 yr with singleton pregnancy posted for Cesarean delivery under spinal anesthesia (with and without preeclampsia). Doses of carbetocin included 10 μg, 20 μg, 40 μg, 60 μg, 80 μg, 100 μg, or 120 μg, with 20 μg for the first patient of either group and then successively decided by response to the bolus in the previous patient in the respective group. After a "failed" dose of carbetocin bolus, the subsequent patient in that group received the next highest dose. In the case of a "successful" dose, we decreased it to the lower dose with a probability of 1/9; otherwise, it remained unchanged. The determinant of a successful dose was satisfactory uterine tone at 2 min after carbetocin, along with no need for any additional uterotonic intraoperatively. RESULTS: The ED CONCLUSION: The dose requirement of carbetocin to prevent intraoperative uterine atony in patients with preeclampsia is 1.5 times greater than in those without the disease.